biostudies-literatureUnknown14(21)Mahana I<h4>Background</h4>Our objective was to assess real-world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.<h4>Methods</h4>We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified.<h4>Results</h4>We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55-73]). Patients were followed for a median of 3037.0 days (IQR, 2808-3221) before mavacamten initiation and for 240 days (IQR, 117-407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new-onset AF/AFL requiring therapy occurred in 125 patients (5%) andJournal of the American Heart Associatione042488https://www.ebi.ac.uk/biostudies/studies/S-EPMC12684520biostudies-literatureCharacteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.PMC12684520Mahana IKamna DNguyen OMasri AElman MRChen HMejia ATVolk HfalseCharacteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.<h4>Background</h4>Our objective was to assess real-world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.<h4>Methods</h4>We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified.<h4>Results</h4>We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55-73]). Patients were followed for a median of 3037.0 days (IQR, 2808-3221) before mavacamten initiation and for 240 days (IQR, 117-407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and2025-01-01T00:00:00Z2025 Nov2026-06-05T23:55:26.97Z2026-05-23T03:13:48.033ZS-EPMC126845204114736810.1161/JAHA.125.042488